Angitrim MR 35 mg (Tablet (Modified Release))
Unit Price: ৳ 6.00 (3 x 10: ৳ 180.00)
Strip Price: ৳ 60.00
Medicine Details
Category | Details |
---|---|
Generic | Trimetazidine dihydrochloride |
Company | Globe pharmaceuticals ltd |
Indications
- Add-on therapy for symptomatic treatment of stable angina pectoris in adults
Pharmacology
- First 3-keto acyl CoA thiolase inhibitor (KAT)
- Metabolic anti-ischemic agent
- Inhibits fatty acid pathway
- Transfers oxygen to glucose pathway
- Aerobic oxidation of glucose stops production of lactic acid
Dosage & Administration
- Recommended dose of 35 mg twice daily
- Assess treatment benefit after three months
- Discontinue if no treatment response
Interaction
- No reported drug interaction
- No interaction with beta-blockers, calcium antagonists, nitrates, heparin, hypolipidemic agents, or digitalis preparation
Contraindications
- Hypersensitivity to the active substance or any excipients
- Patients with Parkinson's disease or symptoms, tremors, restless legs movement disorders, severe renal impairment
Side Effects
- Dizziness
- Headache
- Abdominal pain
- Diarrhoea
- Dyspepsia
- Nausea
- Vomiting
- Rash
- Pruritus
- Urticaria
- Asthenia
Pregnancy & Lactation
- No data on use in pregnant women
- Preferable to avoid use during pregnancy
- Unknown excretion in human milk
- Risk to newborns/infants cannot be excluded
- Not recommended during breast-feeding
Precautions & Warnings
- Not curative for angina attacks
- Not an initial treatment for unstable angina pectoris
- Not a treatment for myocardial infarction
Therapeutic Class
- Other Anti-anginal & Anti-ischaemic drugs
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children
Related Brands
- Angimet 20 mg (Tablet) - orion-pharma-ltd
- Angimet MR 35 mg (Tablet (Modified Release)) - orion-pharma-ltd
- Angirid MR 35 mg (Tablet (Modified Release)) - acme-laboratories-ltd
- Angivent MR 35 mg (Tablet (Modified Release)) - square-pharmaceuticals-plc
- Antoris MR 35 mg (Tablet (Modified Release)) - opsonin-pharma-ltd